Global Collaboration Capitalize on CN Bio's recent strategic partnership with Pharmaron to offer integrated Organ-on-a-chip workflows on a global platform, enabling scalable preclinical testing and harmonized supply chains for multinational pharma and CROs.

Toxicology & Bioavailability Leverage the launch of a preclinical toxicology testing kit and the PhysioMimix Bioavailability assay kit to accelerate early risk assessment and ADME profiling, appealing to teams seeking human-relevant data and reduced reliance on animal testing.

Animal-Free Advantage Position CN Bio as a leader in the industry’s shift away from animal testing by delivering human-relevant mechanistic data through organ-on-a-chip platforms, aligning with regulatory incentives and grant funding.

Unified System Upsell Promote the PhysioMimix Core as an integrated platform to speed adoption among academic labs and mid-size biotech firms, while expanding revenue via consumables, plates, and contract research services.

Disease Model Reach Target drug development programs in liver and lung diseases and other multi-organ models, selling disease-specific data packages, validated workflows, and customized CRO services to reduce late-stage risk.